Auteurs Billaud M, Larbret F, Czerucka D
Frontiers in immunology Dec 2023
Nanoblades allow high-level genome editing in murine and human organoids.Auteurs Tiroille V, Krug A, Bokobza E, Kahi M, Bulcaen M, Ensinck MM, Geurts MH, Hendriks D, Vermeulen F, Larbret F, Gutierrez-Guerrero A, Chen Y, Van Zundert I, Rocha S, Rios AC, Medaer L, Gijsbers R, Mangeot PE, Clevers H, Carlon MS, Bost F, Verhoeyen E
Molecular therapy. Nucleic acids Jul 2023
The mechanical phenotypic plasticity of melanoma cell: an emerging driver of therapy cross-resistance.Auteurs Diazzi S, Tartare-Deckert S, Deckert M
Oncogenesis Feb 2023
The mechanosensitive TRPV2 calcium channel promotes human melanoma invasiveness and metastatic potential.Auteurs Shoji KF, Bayet E, Leverrier-Penna S, Le Devedec D, Mallavialle A, Marionneau-Lambot S, Rambow F, Perret R, Joussaume A, Viel R, Fautrel A, Khammari A, Constantin B, Tartare-Deckert S, Penna A
EMBO reports Feb 2023
Sphingosine-1 Phosphate Receptor Modulators Increase In Vitro Melanoma Cell Line Proliferation at Therapeutic Doses Used in Patients with Multiple Sclerosis.Auteurs Ruetsch-Chelli C, Okuda DT, Rocher F, Tartare-Deckert S, Deckert M, Lebrun-Frenay C
Neurology and therapy Dec 2022
Role of extracellular matrix architecture and signaling in melanoma therapeutic resistance.Auteurs Popovic A, Tartare-Deckert S
Frontiers in oncology Sep 2022
The Stress-Responsive microRNA-34a Alters Insulin Signaling and Actions in Adipocytes through Induction of the Tyrosine Phosphatase PTP1B.Auteurs Cornejo PJ, Vergoni B, Ohanna M, Angot B, Gonzalez T, Jager J, Tanti JF, Cormont M
Cells Aug 2022
Emerging Role of Deubiquitinating Enzymes (DUBs) in Melanoma Pathogenesis.Auteurs Ohanna M, Biber P, Deckert M
Cancers Juil 2022
Secretion of IL1 by Dedifferentiated Melanoma Cells Inhibits JAK1-STAT3-Driven Actomyosin Contractility of Lymph Node Fibroblastic Reticular Cells.Auteurs Rovera C, Berestjuk I, Lecacheur M, Tavernier C, Diazzi S, Pisano S, Irondelle M, Mallavialle A, Albrengues J, Gaggioli C, Girard CA, Passeron T, Deckert M, Tartare-Deckert S, Prod'homme V
Cancer research May 2022
Discoidin Domain Receptor 2 orchestrates melanoma resistance combining phenotype switching and proliferation.Auteurs Sala M, Allain N, Moreau M, Jabouille A, Henriet E, Abou-Hammoud A, Uguen A, Di-Tommaso S, Dourthe C, Raymond AA, Dupuy JW, Gerard E, Dugot-Senant N, Rousseau B, Merlio JP, Pham-Ledart A, Vergier B, Tartare-Deckert S, Moreau V, Saltel F
Oncogene Mar 2022